On Tuesday, Serum Institute of India announced its efforts to develop a vaccine for Monkeypox, with expectations for promising results within the next year. The World Health Organization declared the Mpox outbreak a public health emergency of international concern on August 14, following a surge in cases primarily in parts of Africa.
India has reported approximately 30 Mpox cases since 2022, with the most recent case identified in March 2024. Adar Poonawalla, CEO of Serum Institute of India, stated, “Given the global health emergency related to the Mpox outbreak, we are actively working on a vaccine to protect millions who might be at risk.” He expressed hope for significant progress and updates within a year.
In response to the outbreak, the Union Health Ministry has increased scrutiny at international entry points, including airports and seaports. Additionally, three hospitals—Ram Manohar Lohia Hospital, Safdarjung Hospital, and Lady Hardinge Medical College—have been designated as nodal centers for the isolation, management, and treatment of Mpox patients.
Serum Institute of India, based in Pune, is one of the world’s largest and most renowned vaccine manufacturers. Founded in 1966, the institute plays a critical role in global immunization efforts, producing a wide range of vaccines for various infectious diseases. It is especially noted for its extensive production capabilities and its commitment to making vaccines affordable and accessible worldwide.
Serum Institute’s portfolio includes vaccines for diseases such as measles, polio, and hepatitis, and it has been pivotal in supporting public health initiatives globally. The organization also engages in research and development to address emerging health threats, making significant contributions to both routine and emergency vaccination programs.
